SMYTHE H A, OGRYZLO M A, MURPHY E A, MUSTARD J F
Can Med Assoc J. 1965 Apr 10;92(15):818-21.
Sulfinpyrazone (Anturan) administered in therapeutic doses over a period of several weeks produced prolongation of platelet survival and reduced turnover but with little change in blood coagulation. The changes in platelet survival and turnover were associated with reduced platelet adhesiveness. It is therefore possible to affect platelet economy in man significantly, without producing corresponding effects on blood coagulation.
在数周时间内给予治疗剂量的磺吡酮(安妥明)可使血小板存活期延长、更新率降低,但对血液凝固的影响很小。血小板存活期和更新率的变化与血小板黏附性降低有关。因此,有可能在不影响血液凝固的情况下显著影响人体的血小板代谢。